Rimiducid (Not yet branded)
Other Medications
Description
Rimiducid is a small molecule dimerizing agent used as a safety switch in cellular immunotherapy protocols for colorectal cancer. It functions specifically to activate engineered safety mechanisms in CAR-T cells and CAR-NK cells that have been modified with inducible caspase-9 (iCasp9) systems. This medication serves as a critical safety control mechanism that can rapidly eliminate infused cellular therapies if severe adverse events occur during treatment.
Mechanism of Action
Rimiducid works by binding to and dimerizing the FK506-binding protein 12 (FKBP12) domains that are incorporated into modified caspase-9 proteins within engineered immune cells. Upon dimerization, the modified caspase-9 becomes activated and triggers apoptosis specifically in the infused CAR-T or CAR-NK cells. This provides clinicians with a pharmacological "off switch" to rapidly clear potentially harmful cellular therapies from the patient's system.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.